Skip to main content

Select Drug Profiles

Rituximab Maintenance and Radioimmunotherapy Are Cost-Effective After First-Line Therapy in Follicular Lymphoma

Switching from Intravenous to Subcutaneous Rituximab Saves Staff Time and Money

2013 Annual Index

Conference Highlights ASH

Chemoimmunotherapy with Fludarabine, Cyclophosphamide, and Rituximab versus Bendamustine and Rituximab in Previously Untreated and Physically Fit Patients with Advanced Chronic Lymphocytic Leukemia

Conference Highlights ASH

Safety and Efficacy of Obinutuzumab (GA101) with Fludarabine Cyclophosphamide or Bendamustine in the Initial Therapy of Patients with Chronic Lymphocytic Leukemia: Results from the Phase 1b GALTON Trial

Conference Highlights ASH

Chronic Lymphocytic Leukemia: A New Treatment Era is Born

Conference Highlights ASH

Head-To-Head Comparison of Obinutuzumab Plus Chlorambucil versus Rituximab Plus Chlorambucil in Patients with Chronic Lymphocytic Leukemia and Coexisting Medical Conditions: Final Stage 2 Results of the CLL11 Trial

Leukemia, Oncology

Idelalisib Improves Outcomes in Heavily Pretreated Patients with CLL

Gazyva for Chronic Lymphocytic Leukemia: First FDA-Approved Breakthrough Therapy in Oncology

Lisa A. Raedler, PhD, RPh

Conference Highlights ASH

Siltuximab: Monoclonal Antibody Relieves Symptoms of Castleman’s Disease

Page 157 of 244
Results 1561 - 1570 of 2438